Bloom Energy's Gigantic Calls: The Mystery Buyer Is a Distraction

The question that followed Bloom Energy around this week — who was buying all those gigantic calls? — was never really about options. It was about edge: the hope that once you know the name behind the trade, you can ride their coattails. And then, conveniently, an answer appeared. A congressional filing showed that Paul Pelosi, Nancy Pelosi's husband, had loaded up on Bloom Energy — and Intel — weeks earlier.

That feels like confirmation. Follow the smart money, be on the right side of the trade. But the identity of the buyer is the story, not the mechanism. The move isn't being driven by who's on the other side of these calls. It's being driven by a price-insensitive index fund that has no choice and no opinion, running on a calendar that has an expiration date.

The most important buyer has no name

Let's start with what actually moves this stock. On September 4, S&P Dow Jones Indices said Bloom Energy would join the S&P 500 effective before the open on September 21, replacing Molson Coors. That's a mechanical event with a date. Every passive fund and ETF that tracks the S&P 500 is now obligated to buy Bloom by then, regardless of what the shares cost or whether the valuation makes sense. That is the difference between a person choosing to buy and a machine that must buy. The biggest buyer in this stock over the next week is not a congressman's portfolio — it's the plumbing of index replication.

This is the part most commentary misses, because the narrative is more fun. A company being promoted to the S&P 500 is treated like a vote of confidence in the AI-power story. It isn't. It's an onboarding process. The demand it creates is guaranteed, dated, and — here's the thing — exhaustible. It runs through September 21 and then it's done.

The disclosed bet was a dip-buy, not a crystal ball

Now the disclosure everyone is trading on. Paul Pelosi bought 10,000 Bloom shares and 100 call options on July 24, then added 5,000 more shares and 100 more calls on July 28 — 15,000 shares and 200 calls in total, with the calls struck at $100 and expiring in June 2027. The filing puts the combined value in congressional disclosure bands of roughly $3 million to $12 million.

Two things are worth noting about what that really was. First, the timing. The July 24 purchase came right after the stock had crashed about 50%, closing that day near $185; the follow-up on July 28 settled near $167. This was buying a beaten-down dip, not foresight about a specific event. Second, the disclosure bands are just floors — the true dollar commitment, in a stock like this, can be several times the reported number. Say what you want about the optics; as a signal, "bought a fallen stock after a 50% crash" reads a lot less like clairvoyance and a lot more like a levered bet that has already paid spectacularly.

The same filing disclosed the second name in that "two stocks" headline: Intel. Options on both. It all feeds the same mainstream narrative — AI power, AI compute. Fine. But a disclosed bet is not a mechanism.

The calls being chased are the crowd hedging itself

Meanwhile the options market is doing what it does in a mania. On September 8, Bloom saw nearly $350 million of single-session options volume — calls outnumbered puts by about 50% — and the stock jumped 11%. Someone is buying enormous call volume. The retail flow data today shows the money is still chasing: retail buys are running ahead of retail sells.

Here is the mechanical reading of "who's buying the gigantic calls." It is the crowd. Momentum chasers levering up on a name that just tripled. When they buy calls, the dealer on the other side sells them and then has to hedge — and that hedging itself props the stock up. So the very flow the market is asking about is, in part, manufacturing its own support.

But look at the positioning beneath the euphoria, and the market is not one-way at all. Implied volatility sits near 77% — the options are pricing in daily moves of roughly 5% in either direction. And despite all the call-buying, put open interest actually exceeds call open interest. A stock with that much call chasing and still more puts parked in open interest isn't a quiet accumulation; it's a heavily hedged battlefield, with sellers and traders bracing for violent two-way swings.

The bull case is real. So is the price.

Give the consensus its due. The underlying story is genuine: Bloom's fuel cells give data centers power without the grid, demand is exploding, second-quarter revenue rose 165% and the company lifted full-year guidance to $3.9–$4.2 billion, capped by a 2.8-gigawatt AI-power deal with Oracle and Brookfield. Joining the S&P 500 is a real milestone. Yes, the stock can still go higher — the mandated index buying doesn't finish until September 21.

Now the flip. This is a stock up roughly 217% year to date, about 84% over the last 120 days, trading at a market value around $69 billion against a forward-revenue guide in the mid-$4 billions and a price-to-earnings ratio north of 270. It's sitting near a price level that had already pulled back from a 52-week high around $351 after running from a low near $61. When the index-replication buying is done on the 21st, the marginal dollar has to come from a discretionary buyer — someone who has a choice — at that multiple.

That's the whole tension of the setup, and it's mechanical, not moral. The forces carrying this stock right now — a date-bound index fund and dealer hedging of momentum calls — both decelerate and eventually stop. The narrative about the congresswoman who bought weeks earlier is how the market explains the move to itself. It isn't what's carrying the price.

So whether you own Bloom or are watching it, the question to ask yourself isn't who bought the calls. It's whether the stock can keep being bought by people with a choice after the machine is done. If you believe AI data-center power demand keeps compounding, the company may well earn its way here — that's a multi-year bet on the product. If you're here because an index fund has an appointment on the calendar, or because a disclosed filing made it feel like you were late, then you're not trading the thesis — you're trading the tail of a scheduled rebalance, and that tail has a date on it.